Aftercare of Childhood Cancer Survivors in Switzerland - the ACCS Switzerland Project

Aftercare of Childhood Cancer Survivors in Switzerland

Sponsors

Lead sponsor: Kantonsspital Aarau

Collaborator: University Children's Hospital Basel
Luzerner Kantonsspital

Source Kantonsspital Aarau
Brief Summary

The Aftercare of Childhood Cancer Survivors in Switzerland (ACCS) study is a multicenter cohort study designed to investigate transition of follow-up care from pediatric oncology to adult care in a prospective and longitudinal way. The investigators collect data on preferences and expectations for follow-up care and transition to adult care by questionnaires in adolescent and young adult survivors of childhood cancer.

Detailed Description

Background: Every year over 300 children and adolescents up to the age of 18 years are newly diagnosed with cancer in Switzerland. Survival after childhood cancer has increased substantially over the last decades and 10-year survival now exceeds 85%. This results in an increasing numbers of childhood cancer survivors - currently around 7,000 survivors in Switzerland. Due to cancer treatment or the cancer itself, a large part of the childhood cancer survivors suffers from late effects. Early diagnosis and intervention can reduce morbidity and mortality due to late effects. Therefore, regular follow-up care, even beyond childhood, is very important, but transition from pediatric to adult follow-up care is a critical point. In Switzerland there are very different aftercare and transition models, although it is unclear which aftercare strategy is the best and meets the needs of survivors. The Aftercare of Childhood Cancer Survivors (ACCS) study aims to fill this gap.

Objectives: The main objective of the ACCS study is to identify the current needs of adolescent and young adult long-term survivors in terms of follow-up care by comparing three different transition practices. The secondary objective is to assess survivors' knowledge on their diagnosis, therapy and follow-up examinations longitudinally.

Methods: ACCS is a multicenter questionnaire-based study, including survivors from three pediatric oncology centers in Switzerland. Eligible survivors who already transitioned to adult care at start of the study once receive a letter explaining the purpose of the study, the study information, the informed consent form, and the questionnaire. The questionnaire asks about cancer knowledge and additionally includes validated scales on cancer worry, self-management skills, ongoing care, and expectations. The survivors send the documents back by a prepaid envelope. Eligible survivors before transition to adult care at start of the study receive a letter explaining the purpose of the study, the study information and informed consent form, and the first questionnaire two to four weeks before the next scheduled follow-up visit. They can either send the documents back before the visit or bring them to the visit. The participants receive three month after the visit a short questionnaire to assess cancer knowledge. Three month after the follow-up visit after transition (15 month after last visit in pure pediatric setting), the participants receive the first comprehensive questionnaire again.

Rationale and significance: There are very different aftercare and transition models in Switzerland, although it is unclear which follow-up care strategy best meets the needs of survivors. The data collected within the ACCS study helps to define which transition and follow-up care strategies and related factors are favoured by adolescent and young adult survivors. Adaption of transition processes to the needs of survivors improve adherence to follow-up care of adult childhood cancer survivors. As late effects increase with increasing time from treatment, adult survivors of childhood cancer are at particular risk to develop late effects and it is important that they continue follow-up care.

Overall Status Recruiting
Start Date February 12, 2019
Completion Date August 2021
Primary Completion Date February 2021
Study Type Observational
Primary Outcome
Measure Time Frame
Cancer Worry as part of transition readiness Change from baseline to 3 month and 15 month
Self-management as part of transition readiness Change from baseline to 3 month and 15 month
Evaluation of needs for ongoing care as part of transition readiness Change from baseline to 3 month and 15 month
Evaluation of expectation for transition as part of transition readiness Change from baseline to 3 month and 15 month
Secondary Outcome
Measure Time Frame
Survivors' cancer specific knowledge Change from baseline to 3 month and 15 month
Enrollment 140
Condition
Intervention

Intervention type: Other

Intervention name: Transition model

Description: Transition of follow-up care of childhood cancer survivors to adult care

Eligibility

Sampling method: Non-Probability Sample

Criteria:

Inclusion Criteria:

- 5-year survivor of childhood cancer

- Diagnosis according to ICCC3 I-XII; Langerhans cell histiocytosis (LCH), Hemophagocytic lymphohistiocytosis (HLH)

- Age at diagnosis <18 years

- Age at study ≥16 years

- At study start in follow-up care at one of the three pediatric oncology centers (group before transition) or transitioned not before 2014 (group after transition).

- Written informed consent

Exclusion Criteria:

- Treatment only by means of surgery and without increased risk of late effects (e.g. teratoma)

- <5 years after therapy of a relapse or palliative situation

- Severe cognitive impairment, which makes it impossible to complete the questionnaire independently

- Insufficient knowledge of the German language

- Informed consent form not signed

Gender: All

Minimum age: 16 Years

Maximum age: N/A

Healthy volunteers: No

Overall Official
Last Name Role Affiliation
Katrin Scheinemann, MD Principal Investigator Kantonsspital Aarau
Overall Contact

Last name: Katrin Scheinemann, MD

Phone: 004162 838 4909

Email: [email protected]

Location
facility status contact investigator
Division of Oncology - Hematology, Department of Pediatrics, Kantonsspital Aarau | Aarau, Switzerland Recruiting Katrin Scheinemann, MD Katrin Scheinemann, MD Principal Investigator Maria Otth, MD Sub-Investigator Sibylle Denzler, MD Sub-Investigator
Division of Oncology/ Hematology, University Children's Hospital Basel | Basel, Switzerland Recruiting Tamara Diesch, MD Tamara Diesch, MD Principal Investigator
Division of Oncology/ Hematology, Department of Pediatrics, Kantonsspital Lucerne | Lucerne, Switzerland Recruiting Bernhard Eisenreich, MD Bernhard Eisenreich, MD Principal Investigator
Location Countries

Switzerland

Verification Date

February 2020

Responsible Party

Responsible party type: Principal Investigator

Investigator affiliation: Kantonsspital Aarau

Investigator full name: Katrin Scheinemann

Investigator title: Division Head of Pediatric Oncology-Hematology

Keywords
Has Expanded Access No
Acronym ACCS
Patient Data No
Study Design Info

Observational model: Cohort

Time perspective: Prospective

Source: ClinicalTrials.gov